Skip to content

Gene Polymorphism of IL17 and IL 23

Association Between Gene Polymorphism of IL17 and IL 23 in Patients With COVID 19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04948515
Acronym
COVID 19IL17
Enrollment
120
Registered
2021-07-02
Start date
2021-06-03
Completion date
2021-12-03
Last updated
2022-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Respiratory Infection

Brief summary

rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Detailed description

Aim Of The Study 1. To evaluate if there is an association between the IL-17, IL-23 gene polymorphism in Patients With COVID 19 by real-time PCR 2. To measure the serum level of IL17 by ELISA in COVID 19 patients by ELISA. 3. To detect if there is an association between gene polymorphism of IL17 and IL23 and severity of a condition in patients with COVID 19 Study design: a cross-sectional study. The blood samples will be collected from patient records in COVID19 isolation hospitals in sohag governorate and isolation department in sohag university hospitals.

Interventions

DIAGNOSTIC_TESTlaboratory test

genotyping of IL 17 and IL23

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients with Covid19 positive PCR

Exclusion criteria

* Patients with Covid19 clinical criteria not confirmed by PCR

Design outcomes

Primary

MeasureTime frameDescription
genotyping of IL 173-6-2021 to 30-8-2021real time pcr detection of different genotypes
genotyping of IL 233-6-2021 to 30-8-2021real time pcr detection of different genotypes
estimation of serum level of IL 173-6-2021 to 30-8-2021measuring serum level of IL 17 by ELISA

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026